Lv2
146 积分 2024-03-08 加入
Glecirasib plus sitneprotafib in patients with KRAS(G12C)-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
19小时前
求助中
Glecirasib plus sitneprotafib in patients with KRAS(G12C)-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
10天前
已关闭
Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancer
11天前
已完结
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)
11天前
已完结
MUC16: clinical targets with great potential
24天前
已完结
Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3- and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer
1个月前
已完结
Design, Structure Optimization, and Preclinical Characterization of JAB-21822, a Covalent Inhibitor of KRAS(G12C)
1个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
2个月前
已完结
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
2个月前
已完结
Overcoming therapy resistance in EGFR-mutant lung cancer
2个月前
已完结
皖公网安备34019202002308
